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Interaction of clozapine 
with metformin in a schizophrenia 
rat model
G. Horvath1,3*, G. Kis1,3, G. Kekesi1, A. Büki1, L. G. Adlan1, E. Szűcs2, H. El Heni1 & S. Benyhe2
The low efficacy of antipsychotic drugs (e.g., clozapine) for negative symptoms and cognitive 
impairment has led to the introduction of adjuvant therapies. Because previous data suggest the 
procognitive potential of the antidiabetic drug metformin, this study aimed to assess the effects of 
chronic clozapine and metformin oral administration (alone and in combination) on locomotor and 
exploratory activities and cognitive function in a reward-based test in control and a schizophrenia-like 
animal model (Wisket rats). As impaired dopamine D1 receptor  (D1R) function might play a role in the 
cognitive dysfunctions observed in patients with schizophrenia, the second goal of this study was to 
determine the brain-region-specific  D1R-mediated signaling, ligand binding, and mRNA expression. 
None of the treatments affected the behavior of the control animals significantly; however, the 
combination treatment enhanced  D1R binding and activation in the cerebral cortex. The Wisket rats 
exhibited impaired motivation, attention, and cognitive function, as well as a lower level of cortical 
 D1R binding, signaling, and gene expression. Clozapine caused further deterioration of the behavioral 
parameters, without a significant effect on the  D1R system. Metformin blunted the clozapine-induced 
impairments, and, similarly to that observed in the control animals, increased the functional activity 
of  D1R. This study highlights the beneficial effects of metformin (at the behavioral and cellular levels) 
in blunting clozapine-induced adverse effects.
Schizophrenia is a chronic and highly impairing neuropsychiatric disease that affects around 1% of the human 
population. In addition to the positive (e.g., delusions and hallucinations) and negative (e.g., asociality, avoli-
tion, and amotivation) symptoms, cognitive deficits (impaired attention, learning, and memory functions) are a 
hallmark of this  disease1,2. Both first-generation (or typical; e.g., haloperidol) and second-generation (or atypi-
cal; e.g., clozapine [CZP], olanzapine, and risperidone) antipsychotics primarily relieve the positive symptoms, 
whereas the negative symptoms and cognitive deficits remain largely unaffected by these  treatments3. Therefore, 
several types of adjuvant therapies (e.g., physical exercise, cognitive training, and procognitive or antidepressant 
drugs) have been proposed in the treatment of patients with  schizophrenia4,5. Metformin (MTF) is a safe and 
effective agent that is widely applied for the management of patients with type 2 diabetes mellitus; however, it 
is also used in the treatment and prevention of the second-generation antipsychotic-induced impairments in 
lipid and glucose metabolism and weight  gain5,6. Several reports have suggested that MTF improves cognition in 
different conditions, including Parkinson’s and Alzheimer’s  diseases7,8; however, no data are available regarding 
its effects on cognitive function in patients with schizophrenia.
Translational research depends on the relevance of animal models that replicate the human disease and 
investigate the mechanisms of action of different potentially beneficial drugs for the treatment of schizophrenia. 
To provide high validity for this disease, a “multiple hit” rat model, termed Wisket, was developed by combining 
developmental (post-weaning social isolation), pharmacological (treatment with the NMDA receptor antago-
nist ketamine), and genetic (selective breeding based on behavioral phenotype for more than 30 generations) 
manipulations. Wisket animals exhibit a wide range of disturbances, including decreased pain sensitivity, sensory 
gating, cognitive impairments, and altered dopamine 2 receptor  (D2R)  functions9–12. Although not included in 
the diagnostic criteria for schizophrenia, several data report decreased pain sensitivity in this disease, and its 
animal  models13. Therefore, we supposed that the evaluation of pain sensitivity might also be an important sign 
of behavioral impairments.
Both human and animal studies have reported conflicting results regarding the effect of CZP on cognitive 
 functions14–18, and only a few studies have suggested beneficial effects of MTF in schizophrenia rodent  models19,20. 
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Therefore, the first goal of this study was to determine the effects of chronic treatment (4 weeks) with CZP, MTF, 
and their combination (MTF_CZP) on several parameters related to the locomotor and exploratory activities 
and cognitive functions of control (Wistar) and model (Wisket) rats in a reward-based learning test (Ambitus).
Clinical and preclinical studies reported significant roles of the dopamine  D1 receptors  (D1Rs) in the impaired 
cognitive disturbance of patients with  schizophrenia21–23. Although the mechanism of action of MTF is not fully 
understood, it seems that both AMP-activated protein kinase (AMPK)-dependent and -independent pathways 
might be responsible for its neuroprotective  activity7. No data are available regarding the effects of MTF on  D1Rs; 
thus, the second aim of our study was to characterize the  D1R-mediated signaling, radioligand binding, and 
mRNA expression in control and Wisket animals in different brain structures, and the potential effect of CZP, 
MTF, and their combination on these parameters.  D1R binding, signaling, and mRNA expression patterns were 
determined in the cerebral cortex (CTX). Moreover, binding and signaling experiments were also performed 
in the olfactory bulb (OB), brainstem, and diencephalon. Finally,  D1R mRNA expression was detected in the 
prefrontal cortex (PFC), striatum, cerebellum, and hippocampus.
Results
In agreement with our recent  studies9,10, Wisket rats showed decreased pain sensitivity  (F(1,74) = 81.46; 
P < 0.001), sensory gating  (F(1,74) = 5.14; P < 0.05), locomotor activity  (F(1,74) = 4.69; P < 0.05), exploratory activity 
 (F(1,74) = 24.05; P < 0.001), and learning capacity  (F(1,74) = 14.89; P < 0.001) compared with the control animals. 
These parameters did not differ significantly between the differently treated groups.
Regarding body weight changes during the treatment period between week 11–14 (Fig. 1), an ANOVA 
revealed significant effects of group  (F(1,68) = 21.27; P < 0.001) and time  (F(8,544) = 256.76; P < 0.001), but not of 
treatment; i.e., the body weight increased continuously in each group up to the restricted-feeding condition (Day 
25, Fig. 2a). Although the Wisket rats had a lower body weight compared with Wistar rats, none of the treat-
ments had significant effects on this parameter. Food consumption was similar in all groups (on days without 
restriction), but decreased significantly with time  (F(5,150) = 61.43; P < 0.001; Fig. 2b).
Regarding fluid consumption, this parameter was significantly affected by treatment  (F(3,30) = 16.98; P < 0.001) 
and time  (F(7,210) = 40.30; P < 0.001). The food restriction was accompanied by a decrease in fluid consumption in 
all groups. The post hoc comparison revealed a significantly higher relative volume of water drinking in Wisket 
compared with Wistar animals between Days 8 and 15 (Fig. 2c). Furthermore, the control, but not the Wisket, 
animals treated with the drug combination exhibited a significantly lower fluid intake compared with the animals 
treated with CZP alone detected on Days 4 and 22. Regarding the analysis of the calculated daily drug intake 
during the whole investigated period, significant effects of treatments were detected for both MTF and CZP 
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Figure 1.  Experimental paradigm (a). Abbreviations: w, age in weeks; KET, ketamine; TF, tail-flick test; PPI, 
pre-pulse inhibition test; MTF, metformin; CZP, clozapine. Experimental paradigm in the Ambitus system 
(b). The Trial 1 and Trial 2 (also Trial 3 and Trial 4) were repeated at intervals of 1 min, with an interval of 3 h 
between Trial 2 and Trial 3. The means of 4 trials/day were analyzed for the Ambitus test and are referred to as 
Day 1–4 in Fig. 3. The background color of the trials refers to the Task applied, as follows. Task 1 (yellow): all of 
the inside and outside boxes were baited (16 rewards); Task 2 (green): the inside boxes alone (8 rewards) were 
baited; and Task 3 (peach): the outside boxes alone were baited (8 rewards).
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 (F(1,36) = 62.60; P < 0.001 and  F(1,34) = 17.97; P < 0.001, respectively; Fig. 2d). The post hoc comparison revealed 
that the MTF intake was significantly lower in the case of the combination treatment compared with the fluid 
containing MTF alone in both control and Wisket animals. Furthermore, the CZP intake in the combination 
treatment was lower compared with the CZP alone in the control, but not in the Wisket, group.
Behavioral results during the 4-day Ambitus test. A repeated measures ANOVA revealed significant 
effects of group, day, and/or group and day interaction on all of the behavioral parameters assessed here (Table 1). 
The separate analysis of data from the control group did not reveal significant effects of treatment (Fig. 3). In 
contrast, significant effects of treatment or time and treatment interaction were detected in the Wisket group 
for most of the obtained parameters, with the exception of locomotor activity (Table 1). Therefore, only the data 
of the four Wisket groups were included in the detailed analyses. It was observed that the MTF treatment alone 
did not produce significant effects on the investigated parameters compared with the water-drinking animals. 
However, CZP treatment led to a decrease in exploration compared with water-drinking animals, which was 
accompanied by a decrease in learning capacity (Fig. 3 b–e). All parameters were improved by the MTF_CZP 
combination treatment, to a level close to that of the water-drinking group.
D1R functional activity. In the  [35S]GTPγS binding assays, the maximal stimulation (efficacy  [Emax]) of 
G-protein and the negative logarithm of ligand potency  (pEC50) were determined after agonist occupation of 
the  D1Rs. Regarding the G-protein activation in the CTX, the  Emax values revealed significant effects of group 
 (F(1,15) = 8.17; P < 0.05) and treatment  (F(3,15) = 3.71; P < 0.05; Fig. 4a). The post hoc analysis showed that both 
MTF_CZP groups had a significantly higher  Emax level compared with their MTF-treated matched pairs. The 
 Emax values also showed significant effects of group  (F(1,15) = 12.57; P < 0.005) and treatment  (F(3,15) = 4.97; P < 0.05; 
Fig. 4a) in the OB. The post hoc comparison revealed that the Wisket animals treated with the MTF_CZP com-
Figure 2.  Time-course curves of body weight (a), food consumption (b), and fluid consumption (c) according 
to group. The symbols indicate significant differences between the Wistar and Wisket groups (*) compared with 
the water-drinking animals (#), the CZP-alone group (x), and the Day 1 values (o). The arrows indicate the 
starting of the food restriction. Differences in MTF (left side) and CZP (right side) uptake (d) observed between 
the single and combined treatments during the whole investigation period. The symbol # indicates significant 
differences between the single and combined treatment groups.
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bination had a significantly higher level of maximal G-protein activation compared with their matched control 
animals and to water-drinking Wisket animals. The brainstem and diencephalon were not affected by any of the 
treatments in this respect. Regarding the  pEC50 values (Fig. 4b), a significant effect of treatment was detected 
in the OB  (F(3,15) = 4.82; P < 0.05), and the post hoc comparison revealed that the MTF_CZP-treated groups had 
higher values compared with their water-drinking counterparts. Furthermore, the diencephalon exhibited a sig-
nificant effect of group on this parameter  (F(1,16) = 6.95; P < 0.05), with lower values detected in Wisket animals. 
No significant effects were observed in the brainstem.
In equilibrium-saturation-binding assays, the maximal number of specific radioligand binding sites (capacity, 
 Bmax) and the affinity of the ligand–receptor interaction (dissociation constant  [Kd]) were established. Accord-
ing to the saturation-binding experiments, significant effects of group  (F(1,16) = 12.77; P < 0.005) and treatment 
 (F(3,16) = 9.42; P < 0.05; Fig. 4c) on the  Bmax values of the CTX were detected, with a lower level of binding observed 
in the Wisket animals. The post hoc comparison uncovered significantly higher values in the MTF_CZP Wistar 
group compared with its water- or MTF-drinking counterparts, and the same trend was detected in the Wisket 
rats. The ANOVA of  Bmax values in the OB revealed significant effects of group  (F(1,15) = 20.22; P < 0.001), with a 
higher level detected in the Wisket animals. The post hoc comparison showed significant differences between 
the control and Wisket animals for the water, CZP, or MTF_CZP treatments, with significantly lower  Bmax values 
detected in the MTF- compared with CZP-treated Wisket animals (Fig. 4c). Regarding the diencephalon, sig-
nificant effects of treatment  (F(3,15) = 5.20; P < 0.05) were observed, i.e. significantly higher binding capacity was 
detected in the MTF_CZP-treated Wistar group compared with water- or MTF-drinking animals. No significant 
effects were observed in the brainstem. The  Kd values were not significantly affected by any of the treatments 
(data not shown).
D1R mRNA expression. The factorial ANOVA of relative mRNA expression values revealed significant 
effects of group in the CTX  (F(1,68) = 22.04; P < 0.001) and cerebellum  (F(1,66) = 5.05; P < 0.05), with a lower level 
detected in the Wisket animals (Fig. 4d). The post hoc comparison showed that the  D1R mRNA expression was 
significantly lower in the cerebellum of the MTF-treated Wisket animals compared with their matched controls. 
An unpaired t-test revealed that the MTF treatment increased the  D1R mRNA expression in the striatum in 
both Wistar and Wisket animals compared with their water-drinking counterparts. No significant effects were 
observed in the PFC and hippocampus.
Discussion
This study characterized the effects of chronic treatment with MTF, CZP, and their combination on several 
behavioral parameters (motor activity and learning function) and  D1R activation, binding, and gene expression 
in different brain structures. It was revealed that none of these treatments significantly affected the behavioral 
profile of control animals. In contrast, CZP treatment caused further impairments in the exploratory activities 
and cognitive functions in Wisket animals compared with their water-drinking counterparts. Although MTF 
alone did not significantly affect these parameters, it blunted the behavioral side effects of CZP. The in vitro results 
showed a region-specific alteration in  D1R expression and/or signaling in several brain regions of the Wisket 
animals, which were influenced primarily by the combination treatment.
Cognitive dysfunction remains an unresolved problem in the successful management of schizophrenia. It is 
well known that this phenomenon is highly dependent on behavioral activity, attention, and motivation, which 
are also impaired in these  patients24–26. Conflicting results are available regarding the efficacy of CZP against 
cognitive symptoms in patients with  schizophrenia3,14–17. Furthermore, atypical antipsychotic treatment is often 
complicated by the development of obesity and diabetes, leading to metabolic syndrome, and these factors have 
Table 1.  ANOVA results for the in vivo measurements.
Parameter Definition
ANOVA analysis for all 
groups Significance: F;(df);p
ANOVA analysis for Wisket 
groups Significance: F;(df);p
Locomotor activity Number of entries into cor-ridors up to 5 min
Group 30.14;(1,68); < 0.001
Treatment NS
Day 9.76;(7,476); < 0.001
Overall exploratory activity Number of box visits up to 5 min
Group 28.78;(1,68); < 0.001
Treatment/Day 1.75;(7,252); < 0.05Day 4.31;(7,476); < 0.001
Group/Day 2.1;(7,476); < 0.05
Baited box exploration
Number of visits into the baited 
boxes visits up to eating all 
rewards related to eating time
Group 18.15;(1,68); < 0.001
Treatment/Day 1.72;(7,252); < 0.05Day 20.25;(7,476); < 0.001
Group/Day 3.13;(7,476); < 0.005
Non-baited box exploration
Number of visits into the 
non-baited boxes visits up to 
eating all rewards related to 
eating time
Group 22.27;(1,68); < 0.001
Treatment/Day 2.08;(9,108); < 0.05Day 21.19;(3,204); < 0.001
Group/Day 5.98;(3,204); < 0.001
Learning capacity (%)
[(eating count)x(300) × 100]/
[number of rewards ) × (eating 
time)]
Group 16.66;(1,68); < 0.001
Treatment/Day 1.72;(21,252); < 0.05Day 25.76;(7,476); < 0.001
Group/Day 4.32;(7,476); < 0.001
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Figure 3.  Time-course curves of the locomotor (a) and exploratory (b–d) activities, as well as the learning 
capacity (e), according to group. The symbols indicate significant differences between the Wistar and Wisket 
groups (*), compared with the water-drinking group (#), and Day 1 values (o).
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also been linked to the increased risk of cognitive  impairments15,27. In agreement with these results, it is very 
important to consider that the second-generation antipsychotics, including olanzapine and CZP, may result in 
sustained hyperglycemia when administered to rats chronically, which can cause detrimental changes in the 
brain and might affect  behavior28,29. These effects are prevented by regulating glucose levels through exercise. 
Of relevance to this study, MTF has also been shown to reverse antipsychotic-induced glucose dysregulation 
in  rats30. Therefore, the well-known effect of MTF on blood glucose levels may be a very important factor that 
might be involved in the beneficial cognitive effects of the co-administration of MTF with a second-generation 
antipsychotic drug. CZP, as many other psychoactive drugs, decreases the activity and operant response perfor-
mance for food reward, which might be attributed to its sedative effects, at least partially, leading to impairments 
in cognitive  functions16,17. In agreement with these results, CZP significantly decreased the exploratory activity in 
the Wisket animals, suggesting a blunted motivation. MTF, which is a first-line agent in the treatment of patients 
with type II diabetes mellitus, can rapidly cross the blood–brain barrier and exert a protective effect on cognitive 
 functions7,8,31. Although patients with schizophrenia are frequently treated with MTF to blunt the antipsychotic-
induced metabolic side effects, its effect on their cognition has not been evaluated. Only two preclinical studies 
have investigated the behavioral effects of MTF in schizophrenia  models19,20. In a rat model induced by the 
NMDA receptor antagonist MK-801, MTF significantly ameliorated the memory impairments in the water 
maze test, but had no effect on the basic anxiety-like levels in normal naive  rats19. In contrast to these data, the 
cognitive function of Wisket rats was not affected significantly by treatment with MTF alone; this difference 
might be attributed to the altered type of schizophrenia model and/or the applied behavioral tests (reward- vs. 
punishment-based tests). Using a mouse model incorporating both MK801 and chronic unpredictable mild stress 
exposures, the signs of psychosis and depression were  replicated20. The administration of triple-drug combina-
tions consisting of two antidepressants plus CZP improved the performance of these animals in behavioral assays. 
Moreover, the addition of MTF to the treatments further improved both the depressive and schizophrenia-like 
behaviors. However, this study did not investigate the cognitive function of these animals, and the combination 
Figure 4.  Results of  D1R signaling, binding, and mRNA expression assays, as indicated by the changes in  Emax 
(a),  pEC50 (b), and  Bmax (c) values and mRNA expression (d) in the different rat brain structures. The symbols 
indicate significant effects of group (X) and treatment (O). The symbols also indicate post hoc significant 
differences between groups (*) and treatments (arc). The blue stars pinpoint significant differences compared 
with the water-drinking Wistar rats, whereas the remaining stars indicate significant differences compared with 
the control matched pairs. Abbreviations: CTX, cerebral cortex; OB, olfactory bulb; PFC, prefrontal cortex.
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of the four drugs might inhibit the determination of the interaction between CZP and MTF. Our results clearly 
showed that the CZP-induced behavioral impairments were effectively improved by MTF co-administration.
There is strong supportive evidence for the role of  D1Rs in cognitive functions, and an insufficient  D1R func-
tion has been linked to working memory impairments, at least partly by affecting the reward  mechanism32–34. 
 D1Rs are widely distributed in the human, primate, and rodent brain, with the highest levels detected in the 
striatum, CTX, and hippocampus; moreover, these receptors can be found in the brainstem, OB, cerebellum, 
and diencephalon (hypothalamus and thalamus)35–39. In agreement with these data, the presence of  D1Rs could 
be detected in all of the investigated areas, with a high level of receptor density  (Bmax) and increased G-protein 
activation  (Emax) observed in the CTX. The  D1R has now been highlighted as an important neurobiological 
target for the treatment of  schizophrenia1,40. Neuroimaging studies in schizophrenia have reported conflicting 
results regarding  D1R density and/or activation in the  brain39,41–43. Thus, in vivo imaging studies of dopaminergic 
neurotransmission in acute schizophrenia have confirmed the upregulation of  D1Rs in the striatum and CTX, 
with no changes detected in the thalamus, temporal cortex, and  hippocampus43. However, other studies found 
a decreased  D1R-binding potential in the frontal cortex of patients with schizophrenia; alternatively, they did 
not find any changes in different cortical  areas39,41,42. There is a large disagreement about the effects of CZP on 
the  D1Rs, i.e., it has been mentioned as an agonist, antagonist, or inverse agonist  ligand33,44. Furthermore, CZP 
has affinity for other neurotransmitter systems (e.g., serotoninergic, histaminergic, adrenergic, and cholinergic) 
implicated in attention, motivation, and/or sedation,; therefore, its disruptive effects may result from combined 
effects on them, leading to depressed spontaneous activity and impaired reward and cognitive  functions33,45. Few 
studies have suggested a connection between MTF and the dopaminergic system; MTF prevented nigrostriatal 
dopamine degeneration and attenuated the development of dyskinesia, but did not affect downstream mediators 
of  D1R hyperactivation in the striatum in models of Parkinson’s  disease8,46.
Our data showed that the most obvious changes occurred in the CTX; the Wisket animals had significantly 
lower gene expression, binding capacity, and G-protein activation, suggesting significant impairments in the 
cortical  D1R function in this schizophrenia animal model. In contrast, previous data revealed that the chronic 
administration of CZP increased  D1R mRNA expression moderately in the rat  cortex37, whereas none of the 
treatments affected this process significantly in our experiments. However, the combined treatment significantly 
enhanced both the  Emax and  Bmax values in this area, which might play role in the beneficial effects of the com-
bined treatment regarding the behavior of Wisket animals.
The OB is rich in neurons containing both GABA and dopamine, and both  D1Rs and  D2Rs are expressed 
in this brain  region38,47. It also plays a significant role in cognitive processes, which might be provided, at least 
partially, through  D1Rs38,48. Surprisingly, both the  D1R binding level and G-protein-mediated transmembrane 
signaling in the OB were higher in Wisket animals, suggesting an increased  D1R density in this structure. Fur-
thermore, the combined treatment caused a significant enhancement in the efficacy of G-protein activation in 
these animals, and a similar trend was detected in the control animals, which was accompanied by a lower level 
of ligand potency. It cannot be excluded that these effects might also play role in the beneficial effects of combined 
treatments observed in the Wisket group.
The activation of  D1Rs in different nuclei of the brainstem and diencephalon may be involved in the regula-
tion of multiple physiological functions (e.g., feeding, pain sensation, sensory gating, and circadian rhythm), 
which are also disturbed in patients with  schizophrenia36,49. No changes were observed in the brainstem, whereas 
a higher ligand potency (i.e., lower  pEC50 values) was detected in the diencephalon of Wisket animals. Fur-
thermore, the combination-treatment-induced enhancement of the  Bmax, without changes in the  Emax values, 
observed mainly in the control animals, suggests that the enhanced density of binding sites was accompanied 
by a decreased G-protein activation in the diencephalon.
Regarding the region-specific mRNA expression of  D1Rs, clinical data have revealed decreased expression 
of the  D1R transcript in the PFC of patients with schizophrenia, whereas the hippocampus and caudate nucleus 
did not exhibit  alterations32,50. Furthermore, subchronic exposure to an NMDA receptor antagonist (as a schizo-
phrenia model) downregulated the  D1R mRNA in the  PFC21, similar to the tendency found here in Wisket rats. 
Only one study showed that subchronic treatment with CZP did not reverse the decrease in frontal cortex  D1R 
density, as assessed using post-weaning isolation rearing; rather, it increased its  affinity22. In contrast, we did 
not find any effects of CZP treatment on  D1R mRNA expression, which might be attributed to differences in the 
models and/or the treatment paradigms.
In agreement with earlier data, no significant differences were observed between the two groups regarding 
 D1R mRNA expression in the striatum and hippocampus; moreover, chronic administration of CZP did not 
modify this process in  rodents37,39,50. However, MTF administration alone caused a significant increase in  D1R 
expression in the striatum in both groups, without any consequence for the behavioral parameters. In addition 
to motor coordination, the cerebellum is also well known for its role in cognition, and schizophrenia is associ-
ated with alterations in cerebellar  function51,52. Consistent with this role, the decreased  D1R mRNA expression 
detected in the Wisket animals may also be involved in their behavioral impairments.
In summary, the in vitro data revealed an impairment of the  D1R system in the Wisket animals; moreover, the 
CZP treatment alone did not significantly modify any of the in vitro parameters in the two groups. In contrast, 
the combined treatment had significant effects in several brain structures in both groups in the signaling and 
binding experiments; primarily, it enhanced the maximal G-protein activation and maximal  D1R binding in the 
CTX in both groups. Although the changes in the  D1R functions evoked by the combination therapy were not 
accompanied by behavioral alterations in the control animals, it can not be excluded that the improvement in 
 D1R function observed in the Wisket animals stemmed from the beneficial effects of the drug combination. As 
discussed above, the two drugs can influence several other systems that are involved in cognitive functions; thus, 
the complex interaction between the different transmitter systems might have led to the beneficial effects of this 
combination observed in the Wisket animals.
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Limitations
Our work needs to be interpreted with caution, for several reasons. First, it should be mentioned that, in this 
paradigm, we applied a shorter period of ketamine treatment compared with our earlier studies (5 vs. 15 days), 
to protect the animals from the severe side effects of prolonged treatment (e.g., diarrhea)9,10. However, the pres-
ervation of significant differences between the control and Wisket rats in the behavioral tests suggests that the 
model rats also have a schizophrenia-like phenotype in this condition.
As in earlier studies, while applying the drinking water drug-intake method, the rats were housed in pairs 
to avoid the stress of social isolation; therefore, it was not possible to accurately determine the food and fluid 
intake and drug doses in the individual  animals46,53. However, none of the treatments significantly affected the 
body weight of the animals.
Another possible confounding bias of our study is that the amount of drinking water affected the fluid con-
sumption, and it seems that the MTF_CZP combination was distasteful for the animals. This effect was prominent 
in the control rats; however, the lower level of fluid intake did not cause any signs of behavioral impairment. A 
similar trend was detected in the Wisket animals, but it did not reach a significant level, and neither body weight 
nor food consumption were affected by this treatment. Furthermore, the post hoc analysis revealed the absence 
of significant differences in fluid intake between the CZP- and combination-treated Wisket animals at any of the 
investigated time points. Despite the lower fluid intake observed in the MTF_CLZ groups, the doses of the CZP 
and MTF intake were in agreement with previous  studies8,15. Thus, even lower doses of CZP (1–10 mg/kg/day) or 
MTF (50 mg/kg) produced effects on cognitive  functions15,16. Therefore, we concluded that the beneficial behavio-
ral effects of the combined treatment can be attributed to MTF, rather than the slightly lower level of CZP intake.
Since both CZP and MTF have significant effect on carbohydrate  metabolism54, a major limitation of this 
study is that the glucose metabolism was not investigated. Thus it can not be excluded that the interaction of 
MTF and CZP on metabolic parameters (e.g. through glucagon-like peptide regulation) might also contribute 
to the enhanced cognition that we  observed55. Therefore, further studies are needed to determine the glucose 
metabolism in Wisket animals in this experimental paradigm to provide valuable information about the antip-
sychotic-induced metabolic syndrome and its improvement by an antidiabetic drug.
It is perfectly clear that a correlation analysis between the behaviors and the  D1R system would have provided 
valuable data about the relationship between them. During the behavioral studies, it was possible to test the 
experimental animals individually. In in vitro measurements, however, we combined tissue samples from several 
animals belonging to the same experimental group, especially during radioligand binding tests. There were two 
main reasons for this approach: (1) the large number of test samples necessary for determining the concentration 
dependence of the ligand binding parameters over a wide range and (2) the requirement for a protein content of 
the cell membrane fractions used in the receptor binding experiments of at least 100 µg in each reaction tube. 
To fulfill these two conditions, we were forced to combine samples from the brain areas of different animals. 
Combining tissue samples from different animals in this way is common practice in experiments carried out for 
biochemical  purposes56. The preparation procedure adopted here allowed the relatively accurate determination 
of each measurement parameter. Therefore, our data are suitable for the comparison of receptor function or 
mRNA expression in various brain areas; however, in our opinion, they cannot be directly compared with data 
from the in vivo studies. For these reasons, we could not perform such a correlation analysis.
Conclusion
Taken together, the results obtained here demonstrates that CZP, MTF, and their combination did not affect 
behavioral parameters in control animals in a reward-based learning paradigm. In contrast, CZP caused further 
impairments in Wisket animals, an effect that was blunted by MTF co-treatment. Because patients with schizo-
phrenia are frequently treated with MTF to decrease the metabolic side effects of antipsychotics, the effects of 
MTF on cognition in this patient group should also be determined. In agreement with human studies, the cortical 
 D1R mRNA expression, binding, or signaling was decreased in the Wisket animals and was affected primarily 
by the combined treatment with CZP and MTF.
Methods
Animals. Male Wistar (control) and Wisket rats were included in this study. All experiments were car-
ried out with the approval of the Hungarian Ethical Committee for Animal Research (registration number: 
XIV/1248/2018) and in accordance with the guidelines set by the Government of Hungary and EU Direc-
tive 2010/63EU for animal experiments. It is confirmed that the study was carried out in compliance with the 
ARRIVE guidelines. Animals were kept under a 12 h light/dark cycle with conditions of controlled temperature 
(22 °C ± 1 °C) and humidity (55% ± 10%). The behavioral experiments were performed between 8 a.m. and 4 
p.m., under dim lighting. The body weight of the rats was carefully controlled during the whole experiment.
Experimental paradigm. Based on our earlier studies, after weaning (on week 4), both control and Wisket 
rats were tested in the tail-flick test (48 °C hot water) to assess their basal acute heat pain sensitivity (Fig. 1a)9,10. 
Subsequently, the Wisket animals were housed individually for 28 days and treated with ketamine (30 mg/kg/day 
intraperitoneally, for 5 days) during the  2nd week of isolation rearing (Calypsol, Gedeon Richter Plc., Budapest, 
Hungary). The animals were then re-housed (3–4 animals/cage), followed by 1 week of recovery with no treat-
ment. During this period, control animals were socially reared (3–4 animals/cage), with no ketamine treatment.
On week 9, all animals were included in tail-flick and sensory gating (pre-pulse inhibition: PPI) tests. The PPI 
of the acoustic startle response was measured in the Startle and Fear Conditioning System (Panlab, S.L.\Harvard 
Apparatus; Barcelona, Spain) after 12 h of food withdrawal. After a 7.5-min habituation in startle chambers 
using a background noise of 60 dB, rats were exposed to two different trial types: the pulse alone (PA), in which 
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a 40 ms, 115 dB white noise burst was presented; and the prepulse–pulse pair (PP), in which prepulse stimuli 
(20 ms, 85 dB) were followed by the startle stimulus with a latency of 150 ms. Both types of stimuli were applied 
20 times using a random pattern. The interstimulus intervals ranged from 7 to 13 s. The PPI was calculated as a 
percentage using the following equation: PPI (%) = [1 − (startle response for PP) /(startle response for PA)] × 100. 
While more reliable data could have been detected on sensory gating properties by applying multiple different 
prepulse intensities, our preliminary experiments showed that the prolonged detection of startle response led 
to the inactivity of the animals.
On week 10, the basal locomotor and exploratory activities and cognitive function were assessed in the 
AMBITUS 2–2 trials using Task 1 and Task 2 (Ambitus 1, see below and Fig. 1).
On the following week, 4–4 groups of control and Wisket rats were included in a 28-day experiment based on 
the content of the drinking fluid: water, MTF, CZP, or MTF_CZP combination (Fig. 1b). CZP and MTF were dis-
solved and diluted with water. The animals were assigned to the pharmacological treatment groups based on their 
basal test results and body weight to be identical to each other within the control and Wisket groups. The oral 
route (drinking water) was chosen for the administration of the compounds, as it is the preferred translational 
option for potential use in humans. Although daily gavage might represent a more reliable method of substance 
administration, we aimed to avoid the repeated stress it would cause over this extended period (28 days). The 
concentration of MTF was 1 mg/mL, whereas that of CZP was 0.33 mg/mL in the fluid of both the single and 
combined drug-treated groups. The dosing strategy was based on previously published rodent  studies8,15. The 
animals were pair-housed for the whole experimental paradigm, as described  previously46,53. Although this para-
digm precluded the precise measurements of fluid and food consumption of the individual animals, we aimed to 
avoid the effects of social isolation. The body weight and relative food and fluid consumption were determined 
twice a week during the experiment and freshly prepared solutions were provided. Because restricted food avail-
ability was applied 2 days before and during the Ambitus test (see below), the degree of food consumption was 
analyzed only at the phases during which food was freely available.
A 4-day Ambitus test (Ambitus 2) was performed on week 4 of the drug treatments by applying Task 3 and 
Task 2 (see below and Fig. 1b) after a 2-day food-deprivation period. Moderate food restriction was maintained 
throughout the Ambitus test by decreasing the amount of food (10–15 g/day). Drinking fluid was freely available 
during the whole experiment.
The AMBITUS apparatus. The Ambitus apparatus is a rectangular corridor constructed of clear plexiglass 
on a black floor with an external diameter of 80 cm, a width of 8 cm, and a height of 50 cm (www. deakd elta. 
hu), where the rats could move around forward and backward between the  walls10. Each of the four corridors 
has four side-boxes with an equal size (5 × 5 × 5 cm; 2–2 on the internal and external walls; altogether, 16) with a 
food reward (puffed rice: 20 mg). Infrared beams located at the entrance of each aperture allowed the detection 
of nose pokes (exploration), whereas the locomotor activity was detected by infrared beams located midway in 
each corridor, at a 1 ms time resolution.
After the insertion of the food rewards into the side boxes, trials commenced by placing the rats at the same 
starting point within the corridor; thereafter, the experimenter immediately left the  room10. The animals were 
allowed to explore the corridor and collect food rewards for 5 min (cut-off time: 300 s). At the end of each trial, 
the number of food rewards eaten by the animals was recorded and the apparatus was cleaned with 70% etha-
nol. Experiments were recorded using an infrared video device (WCM-21VF, CNB, China) fastened above the 
apparatus. If an animal had eaten all the available rewards, its video recording was analyzed offline to determine 
the time required to complete the task. Three different tasks were applied during the study (Fig. 1b). In Task 1 
(trials 1 and 2 during the baseline measurements), all inside and outside boxes were baited (16 rewards); in Task 
2 (trials 3 and 4 during the baseline measurements and Days 3–4 during the 4-day-long experiment), only the 
inside boxes (8 rewards) were baited; whereas in Task 3 (Days 1–2 during the 4-day-long experiment), only the 
outside boxes were baited (8 rewards). All rats performed two sessions (two trials/session, 1 min apart) of tasks 
per day, one in the morning and another about 3 h later (4 trials/day). Altogether, 16 trials were completed, and 
the means of the daily 4 trials were further analyzed. Table 1 shows the definition of the analyzed parameters in 
the Ambitus system.
Brain extraction. One day after conducting the Ambitus 2 test (Day 29, Fig. 1a) the animals were decapi-
tated and the brains were quickly removed, dissected on dry ice, frozen in liquid nitrogen and stored at − 80 °C 
until further analyses.
Preparation of brain samples for the binding assays. Neuronal membrane fractions were prepared 
from frozen brains for in vitro receptor binding and the functional  [35S]GTPγS (specific activity: 1000 Ci/mmol; 
purchased from Hartmann Analytic, Braunschweig, Germany) binding experiments, according to our previous 
 studies12,57. The protein content of the membrane preparation was determined via the method of Bradford using 
BSA as a  standard58, and the UltimaGold MV scintillation reagent was from PerkinElmer (Boston, USA).
Functional  [35S]GTPγS binding experiments. The functional  [35S]GTPγS binding experiments were 
performed as previously  described59,60, with modifications for optimizing the binding assay stimulated with a 
 D1R  agonist61. Briefly the membrane homogenates were incubated at 30 °C for 60 min in buffer (pH 7.4) com-
posed of 25 mM HEPES, 120 mM NaCl, 20 mM  MgCl2, 1.8 mM KCl, and 1 mM sodium deoxycholate contain-
ing 20 MBq/0.05  cm3  [35S]GTPγS (0.05 nM) and increasing concentrations  (10—10 to  10—5M) of the selective 
 D1R full agonist, SKF81297 (Tocris Bioscience, Bristol, United Kingdom)62. The experiments were performed 
in the presence of excess GDP (10 µM) in a final volume of 1 mL. Total binding was measured in the absence 
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of test compounds, whereas non-specific binding was determined in the presence of 10 µM unlabeled GTPγS 
and subtracted from the total binding. The difference represented basal activity. The reaction was terminated by 
rapid filtration under vacuum (Brandel M24R Cell Harvester), and washed three times with 5 mL of ice-cold 
0.1 M phosphate (pH 7.4) buffer through Whatman GF/B glass fibers. The radioactivity of the dried filters was 
detected in an UltimaGold MV aqueous scintillation cocktail on a Packard Tricarb 2300TR liquid scintillation 
counter.  [35S]GTPγS binding experiments were performed in triplicate and were repeated at least three times.
Saturation-binding experiments. Aliquots of frozen rat brain membrane homogenates were centri-
fuged, thawed, and suspended in 50 mM Tris–HCl buffer (pH 7.4). Because the  D1R antagonist  [3H]SCH 23,390 
(Tocris Bioscience, Bristol, United Kingdom) also possesses high affinity for the 5-HT2  receptors63, 1 µM ket-
anserin (a selective 5-HT2 ligand) was added to the buffer, to block  them64. Membranes were incubated in the 
presence of  [3H]SCH 23,390 in increasing concentrations (0.29–12.01 nM) at 25 °C for 60 min. The non-specific 
and total binding were determined in the presence and absence of 10 µM unlabeled SCH 23,390, respectively. 
The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester) and washed three 
times with 5 ml of ice-cold 50 mM Tris–HCl buffer (pH 7.4) through Whatman GF/B glass fibers. The radio-
activity of the dried filters was detected in an UltimaGold MV aqueous scintillation cocktail on a Packard Tri-
carb 2300TR liquid scintillation counter. The saturation-binding assays were performed in duplicate and were 
repeated at least three times.
Gene expression analysis. RNA extraction and quantitative real-time polymerase chain reaction (qRT-
PCR).
Total RNA was extracted from tissue samples that were homogenized in TriXtract reagent (G-Biosciences, 
St. Louis, MO, USA). Subsequently, the RNA was separated into an aqueous phase by adding chloroform. The 
RNA pellet was dissolved in RNAse-free water after precipitation with isopropyl alcohol and a wash with 70% 
ethanol. The quantity and quality of the extracted RNA were checked using a Genova Nano micro-volume 
spectrophotometer (Jenway) at an optical density of 260 and 260/280 nm, respectively. The samples used for 
further analyses exhibited an absorbance ratio in the range of 1.6–2.0. Equal amounts of RNA were employed 
to synthetize cDNA in each experiment using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA).
PCR was carried out in a thermo cycler (Bio-Rad CFX96 Optics Module) by preparing triplicates of reac-
tions of 10 µl using the iQ SYBR Green Supermix (Bio-Rad). The thermal cycling conditions included an initial 
denaturation step at 95 °C for 30 s and 40 cycles of denaturation at 95 °C for 10 s, annealing at 59 °C for 30 s, and 
extension at 72 °C for 20 s. The amplicons were subjected to a melting curve analysis. The pair of primers previ-
ously designed by Bangaru et al. was applied in-house to identify glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the endogenous control (forward: 5′–AAG AAG GTG GTG AAG CAG GCG–3′ and reverse: 5′–AGC 
AAT GCC AGC CCC AGC AT–3′)65. Two primer pairs were designed using the National Centre of Biotechnology 
Information reference sequence database (https:// www. ncbi. nlm. nih. gov/ Entrez) to amplify a 92 bp fragment of 
the  D1R mRNA (forward: 5′-GAT CTC TTG GTG GCT GTC CTG-3′ and reverse: 5′-ACC CAG ATG TTA CAA AAG 
GGAC-3′). In the negative controls, the reaction contained RNAse-free water instead of cDNA. The threshold 
cycle (Ct) values were used as reference points and the comparative Ct method (Δ∆Ct method) was implemented 
to achieve relative  quantification66;  2−Δ∆Ct values were used to calculate fold changes in target gene expression 
using the control groups as normalizers.
Statistical analysis. All data are expressed as means ± S.E.M., and significance was set at P < 0.05 level. For 
the statistical analyses, the STATISTICA 13.4.0.14 (TIBCO Software Inc., USA) and GraphPad Prism (Inc., San 
Diego, CA) software were used.
For in vivo experiments, data were evaluated by factorial or repeated measures ANOVA, where the repeated 
measures were days and the factors were group (control, WISKET) and treatment (water, MTF, CZP, and MTF/
CZP). Table 1 provides definitions and denotes the significances of the analyzed behavioral parameters. Post hoc 
comparisons were performed using Fisher’s LSD test.
The radioreceptor binding (saturation curves, one binding site model) and  [35S]GTPγS binding data (sigmoid 
dose response stimulation) were processed by a professional curve-fitting program (GraphPad Prism 5.0.) using 
a non-linear regression analysis. A factorial variance analysis was performed to determine the significance level 
of groups and treatments for the obtained in vitro parameters. The post hoc comparisons were performed by 
using the Fisher LSD test. For the mRNA expression data, the unpaired t-test was also used to determine the 
differences between the different groups compared to the water-drinking control animals.
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